|
gptkbp:instanceOf
|
immunosuppressant
biologic medication
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:FDA
2011
|
|
gptkbp:ATCCode
|
L04AA28
|
|
gptkbp:brand
|
gptkb:Nulojix
|
|
gptkbp:CASNumber
|
1143409-23-2
|
|
gptkbp:composedOf
|
modified CTLA-4 linked to IgG1 Fc region
|
|
gptkbp:contraindication
|
liver transplant patients
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
belatacept
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:protein
|
|
gptkbp:mechanismOfAction
|
selective T-cell costimulation blocker
|
|
gptkbp:relatedTo
|
gptkb:abatacept
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
hypertension
gastrointestinal symptoms
increased risk of infection
post-transplant lymphoproliferative disorder
|
|
gptkbp:target
|
gptkb:CD80
gptkb:CD86
|
|
gptkbp:UNII
|
Q1M7D3JZ5F
|
|
gptkbp:usedFor
|
prevention of organ transplant rejection
|
|
gptkbp:usedIn
|
kidney transplantation
|
|
gptkbp:bfsParent
|
gptkb:CTLA-4
gptkb:L04AA27
gptkb:L04AC10
|
|
gptkbp:bfsLayer
|
6
|